Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
0 competitors in Transthyretin (TTR) Amyloid Cardiomyopathy
View Full LandscapeTarget Indication
Transthyretin (TTR) Amyloid Cardiomyopathy
Clinical Trial
NCT02791230Last updated: 12/19/2025
No patent data available. Pre-approval drugs may not have Orange Book listings.
Vyndaqel
Vyndaqel is indicated for the treatment of transthyretin amyloidosis in adult patients with stage-1 symptomatic polyneuropathy to delay peripheral neurologic impairment.
Vaccines, Pneumococcal
Renal Transplantation
Diabetes Mellitus
Major Depressive Disorder
Complicated Intra-abdominal Infections